EquityFolio

VCYT

NASDAQ Healthcare

Veracyte, Inc.

$46.04

-$0.18 (-0.39%)

Live quote

52w: $29.46 – $60.91

Loading chart…
P/E Ratio56.00
P/B Ratio2.68
EV/EBITDA—
Debt/Equity—
ROE4.78%
ROIC—
Revenue Growth16.01%
Gross Margin70.10%
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Own VCYT? Track it here.

Create a free account to add VCYT to a portfolio and watch your P/L update in real time.

Custom screens, valuation models and backtesting are coming to Pro.

Create a free account